Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

[1]  S. South,et al.  Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. , 2016, The New England journal of medicine.

[2]  Q. Li,et al.  Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia , 2015, Leukemia.

[3]  G. Smyth,et al.  Activated Notch counteracts Ikaros tumor suppression in mouse and human T-cell acute lymphoblastic leukemia , 2015, Leukemia.

[4]  K. Horibe,et al.  IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan , 2013, Cancer medicine.

[5]  Chunhua Song,et al.  Congenital pancytopenia and absence of B lymphocytes in a neonate with a mutation in the ikaros gene , 2012, Pediatric blood & cancer.

[6]  K. Hung,et al.  Ikaros Stability and Pericentromeric Localization Are Regulated by Protein Phosphatase 1* , 2009, Journal of Biological Chemistry.

[7]  A. Ferrando,et al.  Activating Notch1 mutations are an early event in T-cell malignancy of Ikaros point mutant Plastic/+ mice. , 2007, Leukemia research.

[8]  P. Kastner,et al.  Notch Activation Is an Early and Critical Event during T-Cell Leukemogenesis in Ikaros-Deficient Mice , 2006, Molecular and Cellular Biology.

[9]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[10]  A. Perkins,et al.  Widespread failure of hematolymphoid differentiation caused by a recessive niche-filling allele of the Ikaros transcription factor. , 2003, Immunity.

[11]  A. Fisher,et al.  Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. , 2000, Genes & development.

[12]  A. Sharpe,et al.  Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. , 1996, Immunity.

[13]  K. Georgopoulos,et al.  Zinc finger‐mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. , 1996, The EMBO journal.

[14]  K. Georgopoulos,et al.  A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma , 1995, Cell.

[15]  A. Sharpe,et al.  The ikaros gene is required for the development of all lymphoid lineages , 1994, Cell.